CA-PEGASUS-TECH
10.3.2021 13:02:13 CET | Business Wire | Press release
Pegasus Tech Ventures (“Pegasus”), a global venture capital firm based in Silicon Valley, announced a partnership with Japan’s television shopping giant Japanet Holdings (“Japanet”) to establish a $50 million corporate venture capital fund to invest in innovative startups around the globe.
Japanet, headquartered in Nagasaki, Japan, is well-known for its home shopping services and now is expanding into other business sectors. The company recently started a new project to build “Stadium City” in Nagasaki, Japan, which will open in 2024. Centered on a sports stadium, the project includes the development of mixed-use facilities such as business offices, retail stores, hotels, and live event arenas, aiming to make it a Nagasaki landmark that will revitalize the local and regional community. Japanet is also committed to the enrichment of elderly life and to providing educational support for children around the globe.
Through the fund with Pegasus, Japanet aims to create value by funding new ideas and collaborating with startups that develop innovative technologies. The fund plans to invest in Silicon Valley and other parts of North America, as well as in Israel, Europe and Asia.
“We at Japanet Group would like to find high-potential startups with talented entrepreneurs and help them succeed and contribute real value to the world. Using a venture fund, we would like to find cutting edge startup technologies that we can use in the Nagasaki 'Stadium City' project, so that we can provide new services, such as child education, elder care, hospitality, and other services that can help with the betterment of people’s lives,” said Akito Takata, President and CEO of Japanet.
"We will leverage our global network to introduce Japanet to top-tier startups,” said Anis Uzzaman, Founder and CEO of Pegasus Tech Ventures. “By making the connection, both the startups and Japanet benefit. Our goal is to create a global innovation platform that supports the growth of our portfolio companies and the success of our corporate partners.”
Pegasus will deploy its team in Silicon Valley and in 15 other regions around the world to find the best startups and connect them with Japanet and Pegasus’ extensive network of corporate partners.
Pegasus has established venture investment funds with over 35 global corporations, including Aisin Seiki, Sojitz Corporation, SEGA SAMMY HOLDINGS, Sunny Health, CAC Holdings Corporation, Teijin Limited, Infocom Corporation, Innotech Corporation, and ASUS, among others.
About Japanet Holdings Co., Ltd.
Based on a corporate vision, "The joy of living now," Japanet operates a home shopping business, as well as a major sports related business designed to revitalize the local and regional community. In order to enrich the "now," Japanet is also working to enhance healthcare services and to address other social issues, such as educational support for children around the world, and support for disaster-stricken areas. For more information, please visit the website https://corporate.japanet.co.jp/ .
About Pegasus Tech Ventures
Pegasus Tech Ventures is a global venture capital firm based in Silicon Valley with $1.5 Billion in Assets Under Management. Pegasus offers intellectual and financial capital to emerging technology companies around the world. In addition to offering institutional investors a top-tier venture capital investment approach, Pegasus also offers a unique Venture Capital-as-a-Service (VCaaS) model for large, global corporations that wish to partner with cutting-edge technology startups. Some of the 35+ corporate partners that have signed up to work with Pegasus include ASUS, Aisin, SEGA, Sojitz, and Omron. These corporations are able to have access to 180+ Pegasus portfolio companies such as SpaceX, 23andMe, SoFi, Bird, Color, App Annie, and many more. To learn more, visit www.pegasustechventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom